Chimerix Inc (CMRX) - NASDAQ
  • Mon, May 9, 12:50 PM
    | Mon, May 9, 12:50 PM | 1 Comment
  • Mon, May 9, 7:33 AM
    • Chimerix (NASDAQ:CMRX): Q1 EPS of -$0.57 beats by $0.09.
    • Revenue of $1.23M (-0.8% Y/Y) misses by $1.56M.
    • Press Release
    | Mon, May 9, 7:33 AM
  • Mon, Feb. 29, 7:31 AM
    • Chimerix (NASDAQ:CMRX): Q4 EPS of -$0.82 misses by $0.09.
    • Revenue of $3.11M (+168.1% Y/Y) beats by $0.43M.
    • Press Release
    | Mon, Feb. 29, 7:31 AM
  • Fri, Feb. 26, 3:58 PM
    • Achillion Pharmaceuticals (ACHN +7.4%) upgraded to Outperform from Neutral with a $10 (36% upside) price target by Baird
    • Insulet (PODD +8.5%) upgraded to Buy from Hold with a $40 (25% upside) price target by Benchmark.
    • DENTSPLY (XRAY -0.1%) upgraded to Neutral from Sell by UBS. Price target raised to $60 (1% downside risk) from $50.
    • PTC Therapeutics (PTCT -29.4%) upgraded Hold from Underperform by Jefferies. Price target lowered to $12 (22% upside) from $18.
    • AbbVie (ABBV -0.3%) upgraded to Buy from Neutral by Citigroup. Price target raised to $65 (16% upside) from $56.
    • Wellcare Health Plans (WCG +0.7%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $114 (24% upside) from $80.
    • Keryx Biopharmaceuticals (KERX +8.7%) downgraded to Neutral from Overweight by JP Morgan.
    • Peregrine Pharmaceuticals (PPHM -62.1%) downgraded to Neutral from Buy with a $0.50 (25% upside) price target by Roth Capital.
    • EXACT Sciences (EXAS -1.8%) downgraded to Neutral from Buy by Roth Capital and Equal Weight from Overweight by Stephens & Co.
    • Radius Health (RDUS -2.8%) downgraded to Hold from Buy with a $37 (23% upside) price target by Jefferies.
    • PTC Therapeutics (PTCT -29.4%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $13 (56% upside) from $90.
    • Orexigen (OREX -31.9%) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $2 (104% upside) from $4.50.
    • Express Scripts (ESRX +2.4%) downgraded to Sell from Hold by Deutsche Bank. Price target lowered to $61(15% downside risk) from $93.
    • Perrigo (PRGO) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $124 (4% downside risk) from $160.
    • Chimerix (CMRX -6.6%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $9 (91% upside) from $13.
    | Fri, Feb. 26, 3:58 PM | 8 Comments
  • Mon, Feb. 22, 12:44 PM
    | Mon, Feb. 22, 12:44 PM
  • Mon, Feb. 22, 9:23 AM
    • Micro cap Chimerix (NASDAQ:CMRX) slumps 29% premarket on robust volume in response to its announcement of additional data from its Phase 3 SUPPRESS study assessing lead product candidate brincidofovir for the prevention of cytomegalovirus (CMV) in patents undergoing hematopoietic cell transplantation (HCT). The data were presented on Saturday at the BMT Tandem Meetings in Honolulu, Hawaii.
    • As reported in December, the study failed to achieve its primary endpoint of a statistically valid reduction in CMV infection at Week 24 following HCT, although a clear antiviral effect was observed at the end of the on-treatment period at Week 14 (24% fewer CMV infections versus 38% for placebo; p=0.002). At Week 24, however, the incidence of CMV infections was almost identical to placebo (51% vs. 52%).
    • The company intends to discuss the data with the FDA and foreign regulators. An intravenous formulation of brincidofovir is under development that has the potential of avoiding the gastrointestinal side effects of the oral version.
    • Previously: Chimerix's lead product candidate flunks late-stage study; shares plummet 73% premarket (Dec. 28, 2015)
    | Mon, Feb. 22, 9:23 AM
  • Mon, Feb. 22, 9:19 AM
    | Mon, Feb. 22, 9:19 AM | 6 Comments
  • Dec. 31, 2015, 12:06 PM
    • TetraLogic Pharmaceuticals (TLOG +34.5%) initiated with Buy rating and $5 (170% upside) price target by Roth Capital.
    • Prima BioMed (PBMD +8.1%) initiated with Buy rating and $6 (400% upside) price target by Roth Capital.
    • Chimerix (CMRX +6.2%) downgraded to Neutral from Overweight JP Morgan. Price target lowered to $15 (69% upside) from $51. Barclays maintains Overweight rating but lowers price target to $12 from $64. Piper Jaffray maintains Overweight rating but lowers price target to $10 from $63. FBR downgrades to Market Perform and reduces price target to $14 from $73.
    | Dec. 31, 2015, 12:06 PM
  • Dec. 30, 2015, 5:38 PM
    • Top gainers, as of 5.25 p.m.: ANFI +8.0%. CMRX +4.2%. RIG +3.1%. SDRL +2.6%. EVEP +2.1%.
    • Top losers, as of 5.25p.m.: TTPH -1.1%. RRC -0.7%. ZION -0.6%.
    | Dec. 30, 2015, 5:38 PM
  • Dec. 30, 2015, 4:28 PM
    | Dec. 30, 2015, 4:28 PM | 12 Comments
  • Dec. 29, 2015, 5:42 PM
    • Top gainers, as of 5.25 p.m.: CREE +2.0%. SDRL +1.9%. FCS +0.8%. XIV +0.6%.
    • Top losers, as of 5.25p.m.: CHK -3.3%. MNK -2.9%. BCEI -2.3%. CMRX -1.4%.
    | Dec. 29, 2015, 5:42 PM | 6 Comments
  • Dec. 29, 2015, 9:20 AM
    | Dec. 29, 2015, 9:20 AM | 16 Comments
  • Dec. 29, 2015, 9:11 AM
    • Bargain hunters continue to take positions in Chimerix (NASDAQ:CMRX). Shares are up 6% premarket on robust volume. The stock collapsed over 81% yesterday after the company announced that brincidofovir failed a late-stage study in preventing CMV infection in patients undergoing hematopoietic cell transplants. Most of yesterday's 26.5M-share turnover occurred after the plunge.
    • Previously: Chimerix's lead product candidate flunks late-stage study; shares plummet 73% premarket (Dec. 28)
    | Dec. 29, 2015, 9:11 AM | 5 Comments
  • Dec. 28, 2015, 12:40 PM
    | Dec. 28, 2015, 12:40 PM | 4 Comments
  • Dec. 28, 2015, 9:14 AM
    | Dec. 28, 2015, 9:14 AM | 1 Comment
  • Dec. 28, 2015, 8:08 AM
    • A Phase 3 clinical trial, SUPPRESS, assessing Chimerix's (NASDAQ:CMRX) lead product candidate, brincidofovir, for the prevention of cytomegalovirus (CMV) infection in patients undergoing hematopoietic cell transplantation (HCT) failed to achieve its primary endpoint.
    • During the on-treatment period through week 14 after HCT, fewer patients in the brincidofovir arm experienced a CMV infection compared to placebo but in the 10-week off-treatment period (week 14 - week 24) more patients in the brincidofovir cohort had a CMV infection versus placebo. There was also an increase in mortality in the brincidofovir arm compared to control but it was not statistically significant.
    • A preliminary analysis suggests that the reason for the endpoint failures was a higher-than-expected incidence of graft-versus-host disease (GVHD) which necessitated a significantly higher use of corticosteroids compared to the control arm. Both GVHD and corticosteroids are risk factors for late CMV infection after the discontinuation of brincidofovir in HCT recipients.
    • Brincidofovir is a broad spectrum antiviral under development for the prevention and treatment of clinically significant infections caused by DNA viruses. It is an oral nucleotide that has shown antiviral activity in vitro against all five families of DNA viruses that affect humans including CMV, adenovirus, BK virus and herpes simplex viruses.
    • The company will host a conference call this morning at 8:30 am ET to discuss the data.
    • Shares are down 73% premarket on robust volume.
    | Dec. 28, 2015, 8:08 AM | 10 Comments
Company Description
Chimerix, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel, oral antiviral therapeutics designed to address unmet medical need. Its proprietary lipid technology to unlock the potential of some of the most broad-spectrum antivirals by... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United States